Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients

Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients

Introduction Regulatory T cell (Treg) therapy has been demonstrated to facilitate long-term allograft survival in preclinical models of transplantation and may permit reduction of immunosuppression and its associated complications in the clinical setting. Phase 1 clinical trials have shown Treg ther...

Bibliografske podrobnosti
Main Authors:	Brook, MO, Hester, J, Petchey, W, Rombach, I, Dutton, S, Bottomley, MJ, Black, J, Abdul-Wahab, S, Bushell, A, Lombardi, G, Wood, K, Friend, P, Harden, P, Issa, F
Format:	Journal article
Jezik:	English
Izdano:	BMJ Publishing Group 2022

Podobne knjige/članki

Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients
od: Susan Dutton, et al.
Izdano: (2022-04-01)

Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation
od: Brook, MO, et al.
Izdano: (2024)

Feasibility, long‐term safety and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients
od: Harden, PN, et al.
Izdano: (2020)

Application of operational tolerance signatures are limited by variability and type of immunosuppression in renal transplant recipients: A cross-sectional study.
od: Bottomley, M, et al.
Izdano: (2016)

Dampened inflammatory signalling and myeloid-derived suppressor-like cell accumulation reduces circulating monocytic HLA-DR density and may associate with malignancy risk in long-term renal transplant recipients
od: Bottomley, MJ, et al.
Izdano: (2022)

Towards regulatory cellular therapies in solid organ transplantation
od: Bottomley, MJ, et al.
Izdano: (2021)

Dampened inflammatory signalling and myeloid-derived suppressor-like cell accumulation reduces circulating monocytic HLA-DR density and associates with malignancy risk in long-term renal transplant recipients
od: Bottomley, M, et al.
Izdano: (2022)

Prevalence of nonmalignant cutaneous disease in renal transplant recipients
od: Lally, A, et al.
Izdano: (2006)

Dampened Inflammatory Signalling and Myeloid-Derived Suppressor-Like Cell Accumulation Reduces Circulating Monocytic HLA-DR Density and May Associate With Malignancy Risk in Long-Term Renal Transplant Recipients
od: Matthew J. Bottomley, et al.
Izdano: (2022-07-01)

Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
od: Carroll, R, et al.
Izdano: (2013)

BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression
od: Katherine A. Barraclough, et al.
Izdano: (2011-01-01)

Update on the long-term complications of renal transplantation.
od: Bottomley, M, et al.
Izdano: (2013)

The prevalence of hyperlipidemia in renal transplant recipients. Associations with immunosuppressive and antihypertensive therapy.
od: Bittar, A, et al.
Izdano: (1990)

Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
od: Hughes, D, et al.
Izdano: (2008)

Cytomegalovirus disease in a renal transplant recipient: the importance of pre-transplant screening of the donor and recipient
od: Ahmed H Mitwalli, et al.
Izdano: (2013-01-01)

Isolated HLA-DP mismatches between donors and recipients do not influence the function or outcome of renal transplants.
od: Rosenberg, WM, et al.
Izdano: (1992)

Immunosuppressant nonadherence profile in kidney transplant recipients and the impact of medication adherence on transplant outcomes
od: Zou Zhi-yu, et al.
Izdano: (2024-12-01)

Complement and renal transplantation: from donor to recipient.
od: Damman, J, et al.
Izdano: (2008)

Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
od: Trzonkowski, P, et al.
Izdano: (2008)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
od: Koen G. A. M. Hussaarts, et al.
Izdano: (2021-01-01)

Rapid Development of Syringocystadenocarcinoma Papilliferum in an Immunosuppressed Liver Transplant Recipient
od: Catherine Zilberg, et al.
Izdano: (2022-05-01)

Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients
od: Mysore K. Phanish, et al.
Izdano: (2020-03-01)

Chimeric antigen receptors and regulatory T cells: the potential for HLA-specific immunosuppression in transplantation
od: Wright, S, et al.
Izdano: (2021)

Regulatory cell therapy in kidney transplantation (The ONE Study): A harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
od: Sawitzki, B, et al.
Izdano: (2020)

Post-transplant outcomes in recipients of living donor kidneys and intended recipients of living donor kidneys
od: Atit A. Dharia, et al.
Izdano: (2022-03-01)

Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
od: Sawitzki, B, et al.
Izdano: (2020)

Use of Donor-derived Cell-free DNA to Inform Tapering of Immunosuppression Therapy in Kidney Transplant Recipients: An Observational Study
od: George Osuchukwu, MD, et al.
Izdano: (2024-04-01)

Evaluation of the XM-ONE assay and the role of endothelial cell antibodies in recipients of living donor renal transplants
od: Procter, J, et al.
Izdano: (2009)

Donors after circulatory death pancreas transplantation
od: Mittal, S, et al.
Izdano: (2017)

Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation
od: Sabrina Wright, et al.
Izdano: (2022-03-01)

Donor-Derived Urothelial Carcinoma in Renal Transplant Recipients
od: Zhiyu Qian, et al.
Izdano: (2022-01-01)

Donor-Recipient Size Mismatch in Paediatric Renal Transplantation
od: J. Donati-Bourne, et al.
Izdano: (2014-01-01)

Transplantation impacts on the oral microbiome of kidney recipients and donors
od: Paul M. Campbell, et al.
Izdano: (2023-11-01)

LIVING DONOR RENAL TRANSPLANTATION IN DONORS WITH INCIDENTAL NEPHROLITHIASIS
od: Patel, N, et al.
Izdano: (2011)

A national survey of immunosuppression adjustment in elderly lung transplant recipients
od: Jade M Kozuch, et al.
Izdano: (2024-12-01)

Neutropenic Enterocolitis in a Pediatric Heart Transplant Recipient on Multiple Immunosuppressants
od: Emily E. Miller, et al.
Izdano: (2018-01-01)

Immunosuppressive regimens on conversion of cytomegalovirus infection to disease in liver transplant recipients
od: Amirhassan Rabbani, et al.
Izdano: (2022-09-01)

Follow-Up Factors Contribute to Immunosuppressant Adherence in Kidney Transplant Recipients
od: Chen T, et al.
Izdano: (2022-10-01)

Switching Immunosuppressive Drugs in Kidney Transplant Recipients: "Show Me the Evidence"
od: Ansari Mohammed, et al.
Izdano: (2006-01-01)

Impact of immunosuppressant therapy on new-onset diabetes in liver transplant recipients
od: Liu FC, et al.
Izdano: (2017-08-01)